Based on this YouTube video's total view count of 2.29K views and industry-standard rates, the estimated total earning is $2 - $5 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore New Monoclonal Antibody for FGFR1 Positive Tumors, Dr. Ilya Tsimafeyeu with 2,290 views, 21 likes, and 4 comments. Experience the impact of this video content that has captured audience attention.

New Monoclonal Antibody for FGFR1 Positive Tumors, Dr. Ilya Tsimafeyeu In this ASCO 2026 presentation, Dr. Ilya Tsimafeyeu from the Bureau for Cancer Research discusses the design and early development of the tumor-agnostic TugNod clinical trial evaluating OMRCA01, a novel monoclonal antibody targeting FGFR1-positive cancers. The study focuses on patients with advanced solid tumors expressing FGFR1, a key driver in cancer growth and tumor microenvironment regulation. While existing FGFR inhibitors target the broader pathway, OMRCA01 is designed as a highly selective FGFR1 antibody. The ongoing phase 1b/2 trial is assessing safety, dosing, and early efficacy across multiple tumor types, including kidney, breast, lung, prostate, and head and neck cancers. Preliminary results are expected in the coming year, highlighting a potential new tumor-agnostic targeted therapy approach in oncology. #FGFR1 #ClinicalTrials #ASCO2026 SUBSCRIBE to get the latest #oncodaily https://www.youtube.com/@OncoDailyTV Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn: https://linkedin.com/company/oncodaily Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram: https://www.instagram.com/oncodailynews/ Follow OncoDaily on TikTok: https://www.tiktok.com/@oncodaily Like OncoDaily on Facebook: https://www.facebook.com/oncodaily/ SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information. Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research. 🔔 New videos every day! 💻 Visit us at https://oncodaily.com/

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.